{"page":{"totalFilteredElements":88},"studies":[{"active":true,"description":"<div>A non-interventional study for Kisqali (Ribociclib) in combination with an aromatase inhibitor in patients with HR+/HER2- stage II and III early breast cancer to evaluate</div><div>real-world effectiveness, safety profile, patient compliance and quality of life (CAROLEEN).</div>","eudractNumber":null,"id":10286,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06830720","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-26T10:41:38+01:00","shortTitle":"CAROLEEN","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation","eudractNumber":null,"id":1659,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02863692","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-07-01T14:28:16+02:00","shortTitle":"CLL-Registry [DCLLSG Register]","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective observational trial to assess treatment sequences and factors that impact<br />overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line<br />studies of the GCLLSG","eudractNumber":null,"id":12152,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06792994","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-06-22T09:35:50+02:00","shortTitle":"CLL2000","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien","eudractNumber":null,"id":3460,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-01-01T11:09:29+01:00","shortTitle":"CML VI - Registerstudie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.","eudractNumber":null,"id":10267,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT06181734","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-09-13T09:23:35+02:00","shortTitle":"CONFIDHENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors<div><br /></div><div>EUPAS1000000752</div>","eudractNumber":null,"id":11840,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":null,"shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors<div><br /><div>EUPAS1000000752</div></div>","eudractNumber":null,"id":11546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-12-16T11:30:49+01:00","shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)","eudractNumber":null,"id":4328,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03374267 ","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-11-30T08:55:28+01:00","shortTitle":"Carat","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Ein Register f&#252;r Befunde und Videos von Endoskopien in der Gastroenterologie","eudractNumber":null,"id":11473,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06920680","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-25T10:02:09+02:00","shortTitle":"ColoReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective NIS to generate real-world-data on Effectiveness and Safety of first-line therapy with Chemotherapy combined with Durvalumab followed by maintenance therapy with Durvakumab or Durvalumab + Olaparib in endometrial Cancer","eudractNumber":null,"id":11842,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06890273","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-02T09:47:08+01:00","shortTitle":"Duolife","therapeutical":false,"therapyLines":[]}]}